Linear mixed‐effects model of QTc prolongation for olmesartan medoxomil
نویسندگان
چکیده
منابع مشابه
A thorough QTc study demonstrates that olmesartan medoxomil does not prolong the QTc interval
Two studies (ROADMAP and ORIENT) evaluating the renoprotective effects of olmesartan medoxomil (OM) in patients with type 2 diabetes suggested OM is associated with increased cardiovascular mortality. We conducted a thorough QTc study to evaluate the effects of OM on cardiac repolarization. A randomized, double-blind, phase 1 study was conducted per E14 Guidance to assess the effects of single ...
متن کاملBenicar (olmesartan medoxomil) tablets label
• Nursing mothers: Choose to discontinue nursing or drug (8.3). • In patients with an activated renin-angiotensin system, such as volumeor salt-depletion, renin-angiotensin-aldosterone system (RAAS) blockers such as olmesartan medoxomil can cause excessive hypotension. In susceptible patients, e.g., with renal artery stenosis, RAAS blockers can cause renal failure (5.2, 5.3). • Geriatrics: No o...
متن کاملParoxetine‐induced QTc prolongation
There have been only two previous reports of paroxetine-induced corrected QT (QTc) prolongation on electrocardiogram (ECG). Here, we report a 43-year-old woman with QTc prolongation (476 ms). She had taken 50 mg of paroxetine for 17 days. Three days after discontinuation of paroxetine, QTc returned to within the normal limits (396 ms). Paroxetine blocks the human ether-a-go-go-related gene (HER...
متن کاملOlmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension
In most patients with hypertension, especially Stage 2 hypertension, adequate control of blood pressure (BP) is only achieved with combination drug therapy. When using combination therapy, antihypertensive agents with complementary mechanisms of action are recommended, for example, an angiotensin receptor blocker (ARB) in combination with hydrochlorothiazide (HCTZ), a beta-blocker + HCTZ, an AC...
متن کاملKetamine-induced QTc interval prolongation
Sir, Ketamine is a noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor. It is widely used as a dissociative anesthetic and is also used as an adjunct in pain management, particularly in opioid-tolerant patients. It blocks calcium channels and depresses sodium channel function as well as having anticholinergic effects. It inhibits the re-uptake of the catecholamines and may hav...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Journal of Clinical Pharmacology
سال: 2015
ISSN: 0091-2700,1552-4604
DOI: 10.1002/jcph.572